LYRA News and Press, Lyra Therapeutics Inc.

WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chi...

2023-04-25 08:55:36 ET Lyra Therapeutics ( NASDAQ: LYRA ) said it had resumed screening and enrollment for its second Phase 3 clinical trial of LYR-210 to treat chronic rhinosinusitis (CRS). LYR-210 is a bioresorbable nasal implant and acts as an alternative to sinus surgery&#...

2023-04-25 08:29:42 ET Baudax Bio ( BXRX ) +74% announces positive top-line final results from phase 2 randomized clinical trial of BX1000. Morphic Holding ( MORF ) +34% as lead asset meets key goal in mid-stage trial. CXApp ( CXAI ) +32% . ZeroFox ...

2023-04-25 08:29:42 ET Baudax Bio ( BXRX ) -74% announces positive top-line final results from phase 2 randomized clinical trial of BX1000. Morphic Holding ( MORF ) -34% as lead asset meets key goal in mid-stage trial. CXApp ( CXAI ) -32% . ZeroFox ...

WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced th...

2023-04-05 09:04:39 ET Summary Lyra Therapeutics is developing a drug-eluting elastomeric matrix for chronic rhinosinusitis (“CRS”) that can be placed in the sinus cavity by an ENT physician during an office visit. The product targets CRS patients who fail topical st...

2023-03-29 16:56:32 ET Lyra Therapeutics press release ( NASDAQ: LYRA ): FY GAAP EPS of -$1.83 misses by $0.05 . Revenue of $1.36M (+369.0% Y/Y). Cash, cash equivalents and short-term investments were $97.9 million as of December 31, 2022, compared to $109.6 millio...

-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in mid-2023 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 -- -- Advancing In-House Manufacturing Capabilities to ...

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced the appointment of John Bishop...

-- Topline Results Expected in Q4 2023 -- -- LYR-220 is Lyra’s Second Product Candidate, Following LYR-210 in Surgically-Naïve CRS patients -- WATERTOWN, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-s...